If you are ready to be part of a growing hematology/oncology pharmacy community, we are ready to welcome you. Your HOPA membership will open doors to new opportunities for volunteerism, collaboration, learning, networking, and more.
At HOPA, we believe that the power of our community lies in our membership. Being a HOPA Member means collaborating and engaging with practitioners from every practice setting around the world, giving you the tools and confidence to provide the best care possible.
Become a Member
HOPA offers membership types ranging from Full membership to Student membership. Apply today and join a world-class community of specialty pharmacists!
Connect and learn from world class Hem/Onc professionals.
A Database of Professionals
As a member of HOPA, you get access to thousand's of professionals through HOPA Central, an online community made for you and your peers to connect and share information and resources through Special Interest Groups (SIGs).
Access professional development, education, and clinical training programs that have been created by hematology/oncology pharmacists for hematology/oncology pharmacists.
There are multiple ways to get involved in HOPA! Serve on a Committee, advisory group, or judge posters at the Annual Meeting! As a member of HOPA, you receive first consideration for all of these positions.
2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
July 26, 2023
The in-person annual Transplantation & Cellular Therapy Meetings of ASTCT™ (American Society for Transplantation and Cellular Therapy) and CIBMTR® (Center for International Blood and Marrow Transplant Research) took place from February 15-19, 2023 in Orla
Professional Cancer Associations Collaborate to Improve Treatment of Anemia in Adult Patients with Myelodysplastic Syndromes
June 26, 2023
The initiative will provide support and guidance to community hematologists/oncologists on the risk-stratification of MDS, selection of evidence-based and novel therapies for the management of anemia in patients with lower-risk MDS, and on best practices
Late Breaking News
Two Trials to Change the Landscape for First-Line Treatment for Advanced or Recurrent Endometrial Cancer
June 26, 2023
The use of molecular classification within endometrial cancer has continued to evolve with the incorporation of biomarker-driven therapy .